Saturday, 25 July 2026
AHPRA discrimination notification findings, Prac payment scheme excludes med students, Cyclophosphamide recall due to
- 01
AHPRA review finds high closure rate for discrimination notifications
AHPRA's internal review revealed that 92% of the 477 notifications related to racism and discrimination were closed without regulatory action, surpassing the average closure rate of 88.6% for all notifications. The review, prompted by a directive from health ministers, assessed how AHPRA handles such complaints, particularly concerning antisemitism and Islamophobia. Of the finalised cases, only 28 resulted in regulatory action, with just five referred to tribunal. AHPRA identified that a significant portion of these notifications, particularly those concerning antisemitism and Islamophobia, were linked to social media.
- 02
Expansion of prac payment scheme excludes medical students
The Prime Minister announced an expansion of the Commonwealth prac payment scheme to include 10 additional health degrees, but medical students remain excluded from this support. This decision has drawn mixed reactions, with the Australian Medical Students Association expressing confusion and disappointment. Various healthcare organisations, including the Rural Doctors Association of Australia and the Australian Medical Association, have voiced concerns about the financial pressures on medical students, particularly those in rural areas. The program is set to begin on 1 July 2027, but critics argue that the exclusion of medical students undermines efforts to address workforce shortages in healthcare.
- 03
Sunny Pharmtech Issues Recall of Cyclophosphamide for Injection
Sunny Pharmtech, Inc. has announced a voluntary nationwide recall of three lots of Cyclophosphamide for Injection, USP, due to the presence of particulate matter identified as steel. The affected products are available in 1g and 2g vials. Currently, there have been no reported adverse events or injuries linked to this contamination. This recall raises important safety concerns regarding the use of this medication.
via FDA MedWatch
- 04
Edwards Lifesciences Reports Strong TAVR Sales Amid Medicare Coverage Anticipation
Edwards Lifesciences reported Q2 sales of $1.74 billion, with transcatheter aortic valve replacement (TAVR) sales reaching $1.26 billion, reflecting an 11.3% year-over-year increase. The company anticipates a Medicare coverage expansion for TAVR, potentially allowing treatment for asymptomatic patients with aortic stenosis, with a decision expected in September. CEO Bernard Zovighian linked the strong TAVR demand to increasing clinical evidence supporting earlier intervention. Analysts suggest that positive outcomes from the upcoming PROGRESS study could further boost TAVR growth.
via MedTech Dive
- 05
Sanofi halts amlitelimab development for eczema due to safety concerns
Sanofi has announced it will cease development of amlitelimab, an experimental drug for eczema, after a review of efficacy and safety evidence. The decision follows mixed results from late-stage trials and reports of potential safety issues, including cases of Kaposi's sarcoma among recipients. Amlitelimab was initially seen as a successor to Dupixent, but its development faced significant setbacks. Sanofi will continue to explore its use in celiac disease, with mid-stage study data expected by year-end.
via BioPharma Dive
- 06
Novo Nordisk seeks injunction against Lilly's obesity drug ads
Novo Nordisk has intensified its legal battle against Eli Lilly by requesting a New Jersey District Court to block what it claims are misleading advertisements for Lilly's obesity drugs. Novo alleges that Lilly's ads falsely suggest superiority of its GLP-1 products over Novo's offerings and that Lilly has disregarded a cease-and-desist order. Lilly has denied these allegations, asserting that its advertising is truthful. Novo's legal team argues that the ongoing ads mislead patients and damage Novo's reputation.
via BioPharma Dive
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.